Wednesday, 12 August 2020

Thermo Fisher to co-develop oncology companion diagnostic with Janssen

13 March 2020 | News

The CDx will support clinical trial enrollment globally

Image credit- shuttershock.com

Image credit- shuttershock.com

Thermo Fisher Scientific has announced that it has signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) in oncology. The CDx will support clinical trial enrollment globally. 

Under the agreement, Thermo Fisher Scientific will collaborate with Janssen Research & Development, LLC scientists to validate multiple biomarkers for use with Thermo Fisher's Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer (NSCLC). Additional indications in oncology may follow as part of the agreement.

Oncomine Dx Target Test is a next-generation sequencing (NGS) assay that contains 46 cancer-related biomarkers and a workflow that features a fast turnaround time and the lowest sample requirements on the market for detection of both DNA and RNA variants.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account